Фармакотерапия и алгоритм лечения болезни Крона легкой и средней степени тяжести с позиций медицины, основанной на доказательствах


Е.А. Белоусова

Болезнь Крона - хроническое воспалительное заболевание желудочно-кишечного тракта, локализующееся в любой его части, но преимущественно поражающее подвздошную и толстую кишку. БК характеризуется рецидивирующим течением и нередко - развитием тяжелых осложнений. На основе недавно проведенного мета-анализа клинических исследований лекарственных препаратов при БК обсуждаются эффективность и безопасность фармакотерапевтических методов лечения этого заболевания. Формулируется алгоритм терапии БК с легким и среднетяжелым течением. Подчеркивается, что на сегодняшний день доказанной терапевтической эффективностью в отношении обострений БК обладают будесонид, системные кортикостероиды и в меньшей степени месалазин. В то же время, вопрос о поддерживающей терапии БК все еще остается открытым.

Литература






  1. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001;121:255–60.
  2. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistence and dependency in Crohn’s disease. Gut 1994;35:360–62.
  3. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cogort of Crohn’s disease patients. Scand J Gasrtroenterol 1995;30:699–706.
  4. Mechjian HS, Switz DM, Watts HD, et al. National Cooperative Crohn’s disease Study. Factors determining recurrence of Crohn’s disease after surgery. Gastroenterology 1979;77(4 Part 2):907–13.
  5. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–63.
  6. Sandborn WJ, Feagan BG. Mild to Moderate Crohn's Disease – Defining the Basis for a New Treatment Algorithm. Aliment Pharmacol Ther 2003;18:263–77.
  7. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. Acta Med Scand 1942;110:557–90.
  8. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin R) in Crohn's disease. Scand J Gastroenterol 1974;9:549–54.
  9. Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981;22:404–09.
  10. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847–69.
  11. Malchow H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–66.
  12. Singleton JW, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979;77:887–97.
  13. Rijk MC, van Hogezand RA, van Lier HJ, et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Ann Intern Med 1991;114:445–50.
  14. Das KM, Eastwood MA, McManus JP, et al. The relationship between metabolites and the response to treatment in inpatients. Gut 1973;14:631–41.
  15. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983;28:833–42.
  16. Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491–95.
  17. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877–83.
  18. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88–92.
  19. Singleton JW, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Dis Study Group. Gastroenterology 1993;104:1293–301.
  20. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632–33.
  21. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278–82.
  22. Hanauer SB, Stromberg U. Efficacy of oral Pentasa 4 g/day in treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Gastroenterology 2001;120:A453 (Abstract).
  23. Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 1995;33:581–84.
  24. Scholmerich J, Jenss H, Hartmann F, the German 5-ASA Study Group. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn’s disease. Can J Gastroenterol 1990;4:446–51.
  25. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521–26.
  26. Thomsen O_, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370–74.
  27. Bitton A, Peppercorn MA, Hanrahan JP, et al. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996;91:1039–40.
  28. Iaquinto G, Sorrentini I, Petillo FE, et al. Pleuropericarditis in a patient with ulcerative colitis in long-standing 5-aminosalicylic acid therapy. Ital J Gastroenterol 1994;26:145–47.
  29. Deltenre P, Berson A, Marcellin P, et al. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 1999;44:886–88.
  30. Fernandez J, Sala M, Panes J, et al. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am J Gastroenterol 1997;92:2302–03.
  31. Brouillard M, Gheerbrant JD, Gheysens Y, et al. Chronic interstitial nephritis and mesalazine: 3 new cases? Gastroenterol Clin Biol 1998;22:724–26.
  32. Calvino J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol 1998;49:265–67.
  33. Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infants: side-effect of prenatal exposure to mesalazine? Lancet 1994;344:620–21.
  34. Corrigan G, Stevens P. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1–6.
  35. Martin F, Sutherland L, Beck IT, et al. Oral 5-ASA versus prednisone in short term treatment of Crohn's disease: a multicentre controlled trial. Can J Gastroenterol 1990;4:452–57.
  36. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97:803–23.
  37. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905–09.
  38. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842–45.
  39. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–32.
  40. Bar-Meir, S, Chower, Y, Lavy, A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998;115:835.
  41. Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870–82.
  42. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn’s disease: A controlled trial. Gut 1978;19:606–10.
  43. Brattsand, R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4:407.
  44. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836–41.
  45. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748–54.
  46. Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509–17.
  47. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: A meta-analysis. Aliment Pharmacol Ther 2000;14:1419.
  48. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209–14.
  49. Lyckegaard E, Hakansson K, Bengtsson B. Compassionate use of budesonide capsules (ENTOCORT EC) in patients with Crohn's disease. Gastroenterology 2002;122:T1665.
  50. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease: A placebo controlled one year study. Gut 1996;39:82.
  51. Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. TheBudesonide Study Group. Gut 1998;42:493.
  52. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology 1999;116:294.
  53. Sutherland L, Singleton J, Sessions J, et al. Double blind. placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071–75.
  54. Allan R, Cooke W. Evaluation of metronidazole in the management of Crohn's disease. Gut 1977;18: A422 (Abstract).
  55. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985;28:81–85.
  56. Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123–27.
  57. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550–62.
  58. Rosen A, Ursing B, Alm T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology 1982;83:541–49.
  59. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23:429–48.
  60. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88:681–84.
  61. Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10–15.
  62. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33–40.
  63. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674–78.
  64. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056–67.



Бионика Медиа